Please ensure Javascript is enabled for purposes of website accessibility
Max Macaluso

Max Macaluso

TMFMassimo

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent articles

Patent Expirations AbbVie Investors Need to Watch

A look at AbbVie's most important patent expirations.


Key Problems Behind Teva's Lackluster 2013

Why are shares of Teva up only 2.7% since the start of 2013?


Market Checkup: 2 Turnaround Stories to Watch

The Motley Fool's health care show, Market Checkup, for Sept. 9, 2013.


What Are the Main Threats to AbbVie's Humira?

A look at the AbbVie's second-quarter results and the pros and cons of selling the world's biggest blockbuster drug.


Johnson & Johnson's Earnings Made Easy

A run-down of this well-known health-care company's second-quarter results.

Catalysts Merck Investors Need to Watch

Which events do Merck investors need to pay close attention to?


Did This Big Pharma Giant Sink or Swim Last Quarter?

A look at Pfizer's top and bottom lines in the second quarter.


Market Checkup: Spotlight on Gilead

This edition of the Fool's health care show focuses on biotech company Gilead.


Market Checkup: Spotlight on AbbVie

A deep dive into AbbVie, a brand new company with a long history.


One More Big Pharma Bribery Scandal?

Another drugmaker faces claims of misconduct in China.

Why Rigel Investors Had a Dose of Disappointment Today

Shares of Rigel slid more than 13%. Where does this biotech stand today?


The Biotech Buyout Investors Have Been Waiting For

It's official: Amgen is acquiring Onyx Pharmaceuticals.


Market Checkup: A Biotech Buyout and Another Big Pharma Scandal Brewing in China?

The Motley Fool's health-care show "Market Checkup" for Aug. 26, 2013.


3 Reasons to Buy Bristol-Myers Squibb

Shares of this drugmaker have been on a steady rise since the start of 2013 -- are there any reasons left to buy?


Opportunities Bristol-Myers Squibb Investors Need to Watch

What are Bristol-Myers Squibb's biggest opportunities?

What's Behind Bristol-Myers Squibb's High Valuation?

Shares of Bristol-Myers Squibb have soared this year --- but what's been driving this growth?


Market Checkup: An In-Depth Look at Bristol-Myers Squibb

A close look at pharmaceutical company Bristol-Myers Squibb's last quarter, upcoming catalysts, and reasons to buy and sell the stock.


Market Checkup: Headlines for August 15, 2013

The Motley Fool's health-care show, "Market Checkup," for August 15, 2013.


Merck's Second Quarter: Highlights Investors Need to Know

Merck's total revenue dropped more than 10%, but it wasn't all bad for the drugmaker last quarter.


Time to Panic About Pfizer's Upcoming Patent Expirations?

Intellectual property is the lifeblood of the pharmaceutical industry -- how is Pfizer's patent portfolio holding up?